Latest news with #Ras
Yahoo
6 days ago
- General
- Yahoo
AAA warns of increased teen driving risks during summer
ORCHARD PARK, N.Y. (WIVB) — Memorial Day marked the beginning of the '100 Deadliest Days,' a stretch of summer where fatal crashes involving teen drivers rise significantly. AAA is urging both parents and teens to take extra precautions on the road. 'This time period from Memorial Day to Labor Day is when fatal teen crashes increase dramatically,' said Elizabeth Carey, director of public relations for AAA. 'The latest numbers from 2023 show that 863 people were killed during that summer. That's about eight people per day, compared to seven during the rest of the year. We want to educate people, share information and curb this trend.' AAA officials say some of the biggest distractions for teen drivers are phones and passengers. 'One of the bigger distractions for a new driver, believe it or not, is other people in the vehicle with them,' said Michael Formanowicz, AAA's manager of driver training. 'The phone is a distraction because if they're texting or talking, their eyes may not be on the road, and they're not thinking about the process of driving. The same thing happens if they're talking to passengers.' Teen driver Erynn Ras said she knows how tempting it can be to check her phone, especially during the summer months. 'My phone is probably my biggest distraction,' Ras said. 'Hearing the notification or seeing it on CarPlay definitely makes me want to grab it, especially in the summer when we're not in school and there's a lot going on during the day.' To resist the urge, Ras keeps her phone in the middle console or glove compartment while driving, something AAA encourages, especially among parents, who often serve as role models for young drivers. 'We always encourage parents to exhibit the best driving skills they possibly can,' Formanowicz said. 'That means staying undistracted, coming to complete stops, using head checks when merging, those behaviors are important.' AAA recommends families have early and ongoing conversations with their teens about safe driving habits throughout the summer. Gwyn Napier is a reporter who joined the News 4 team in 2025. See more of her work by clicking here. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Irish Examiner
22-05-2025
- Sport
- Irish Examiner
Donegal's Doogan takes Rás yellow as Perrett clinches stage two in Clifden
The yellow jersey changed hands after the second day of this year's Rás Tailteann proved to be just as stern a test of the riders' grit and guts as the first. Donegal's Odhran Doogan, representing Cycling Ulster, surged into the leader's colours taking the yellow jersey from Tim Shoreman (Wheelbase-Cabtech-Castelli) after 170.9km of hard road from Charlestown, Co Mayo south to Clifden, Co Galway. Englishman Will Perrett came out on top to take stage two honours and admitted it hadn't been easy going. "It was a really, really tough stage," said the DAS Richardsons rider. "This final run-in, it was just chopping off into the crosswind and that was so tough. I saw I had the gap and just committed. I managed to stay away [on my own]. I'm really happy. It's my first win at the Rás." Nottingham-born Perrett would have been claiming the yellow jersey were it not for a crash 3.5km from the end of the opening day's stage but has his eyes on moving up. The morning's leader Shoreman couldn't reel in a break from the main group but Doogan and a smaller chasing pack caught up with that leading bunch and he managed to finish third in the stage to take command at the top, thanks to his points tally from the climbs and sprints. In the process Doogan becomes the first ever Donegal man to wear the leaders yellow jersey of the Ras. Friday's third stage will see the riders set off from Cong, Co Mayo and then take the scenic route down the Wild Atlantic Way before an exciting end awaits them. Fans are likely to see a sprint finish as the rivals come into Miltown Malbay in Co Clare. Elsewhere Olav Kooij sprinted to victory on stage 12 of the Giro d'Italia as Isaac Del Toro retained the pink jersey in Viadana. Kooij was helped by a superb lead-out from Visma-Lease A Bike team-mate Wout Van Aert, with Casper van Uden second over the line ahead of Britain's Ben Turner. The 172km stage from Modena, the first opportunity for the quick men in a week, came down to the final few bends of a technical finish left slightly damp by earlier rain in Viadana, and Van Aert used all his experience to win the fight for position going into the final sharp left-hander. Team Picnic PostNL's Van Uden tried to go long with his sprint after being left with a slight gap as the road straightened out, but Kooij kept his cool to take the win while the Ineos Grenadiers' Turner held off Mads Pedersen for the last step on the podium. A small crash in the peloton with around one kilometre left to go neutralised the times for the overall standings, allowing the general classification contenders to sit up. Del Toro leads by 33 seconds from his UAE Team Emirates team-mate Juan Ayuso with Bahrain-Victorious rider Antonio Tiberi third. Bonus seconds saw Wednesday's stage winner Richard Carapaz move up to fourth, on the same time as Kooij's team-mate Simon Yates in fifth, one minute and 11 seconds off pink. With files from PA
Zawya
01-05-2025
- Business
- Zawya
RAKEZ leadership visits China to boost bi-lateral business ties
Ras Al Khaimah: Ras Al Khaimah Economic Zone (RAKEZ) concluded a high-level delegation—led by its Group CEO Ramy Jallad—to China, aimed at deepening bilateral economic cooperation and opening new avenues for strategic partnerships. The visit underscores RAKEZ's commitment to building global business ecosystems and facilitating Chinese companies' expansion into the Middle East. As part of the visit, the RAKEZ delegation held impactful B2B meetings with leading Chinese enterprises across a spectrum of industries including rubber manufacturing, steel engineering, wood research, science and technology, IT, real estate, and e-commerce. The engagements showcased the growing interest of Chinese businesses in leveraging RAKEZ's strategic advantages to tap into regional and global markets. A key highlight of the mission was the China (Zhejiang) – UAE Ras Al Khaimah Economic and Trade Symposium, which RAKEZ conducted in partnership with Zhejiang's Department of Commerce. During the symposium, RAKEZ presented a comprehensive overview of Ras Al Khaimah's economic landscape, tailored industrial zones, and investor-centric business solutions. In a continuation of this engagement with Zhejiang Province, a delegation from Wenzhou City also visited Ras Al Khaimah to sign a Memorandum of Understanding (MoU) aimed at enhancing cooperation and investment flows between the two regions. The MoU was signed by RAKEZ Chief Commercial Officer Anas Hijjawi and Wenzhou Executive Deputy Director Ji Xiangrong. The RAKEZ delegation also visited Tianjin Port Free Trade Zone to explore collaborations. The discussions build on the strategic MoU signed between RAKEZ and Tianjin Port Free Trade Zone in September 2024, highlighting a deepening commitment to long-term cooperation. Simultaneously, a team from Tianjin Port Free Trade Zone visited Ras Al Khaimah to explore business opportunities and further strengthen ties, exemplifying the dynamic exchange between the two regions. Ramy Jallad, Group CEO of RAKEZ, said: 'At RAKEZ, we believe that impactful economic partnerships are built on the foundation of integrated business environments that empower investors to establish with confidence, grow sustainably, and expand into new markets. Our visit to China is a tangible step toward deepening collaboration with one of our most strategic global partners. We are focused on delivering flexible, investor-centric solutions that support companies across various sectors in accessing the Middle East and Africa. With advanced infrastructure, progressive regulatory frameworks, and comprehensive digital services, our vision is for RAKEZ to serve as the launchpad for Chinese businesses seeking regional and global leadership.' Ras Al Khaimah continues to position itself as a strategic destination for Chinese investors. Its location offers seamless connectivity to the MENA region and beyond, while businesses benefit from set-up and operational costs around 40% lower than other global hubs. The emirate's stable and investor-friendly environment is supported by a strong legal and regulatory framework, offering companies both free zone and non-free zone options tailored to industries such as tourism, hospitality, real estate, manufacturing, e-commerce, trading, hi-tech, logistics, digital services and more. Investors enjoy comprehensive support through RAKEZ's one-stop shop for licensing, facilities, visas, and administration, with the added convenience of a dedicated mobile app for digital setup and remote management. Today, RAKEZ is home to hundreds of Chinese companies operating across a broad range of sectors, including LED lighting, engineering, packaging, recycling, and F&B. Over the years, RAKEZ has steadily strengthened its ties with the Chinese business community through regular delegations, promotional roadshows, and hosting media representatives from key Chinese cities, affirming Ras Al Khaimah's pivotal role in advancing the China-UAE partnership and supporting the Belt and Road Initiative in the region. As part of its ongoing commitment to facilitating Chinese investment, RAKEZ has appointed dedicated representatives in Shenzhen and Shanghai to provide direct support to businesses exploring opportunities in the emirate. For more information, please contact: Cleo Eleazar, Public Relations & Events Manager, RAKEZ Email:
Yahoo
30-04-2025
- Health
- Yahoo
Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Ras Inhibitor Resistant Lung Cancer at the 2025 AACR Annual Meeting
Both REQORSA Alone and in Combination with LUMAKRAS® Demonstrated Robust Anti-Tumor Effects in Ras Inhibitor Resistant Non-Small Cell Lung Cancer AUSTIN, Texas, April 30, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators presented positive preclinical data for Reqorsa® Gene Therapy (quaratusugene ozeplasmid), for the treatment of KRASG12C mutant non-small cell lung cancer (NSCLC). This data were presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting being held April 25-30, 2025 in Chicago, Illinois. "We are pleased to have this positive preclinical data presented before an audience of the world's leading cancer researchers, which provides further support for the therapeutic potential of REQORSA both alone and in combination with targeted therapies in NSCLC," said Ryan Confer, President and Chief Executive Officer at Genprex. "We believe REQORSA could be a potential therapeutic treatment for Ras inhibitor resistant lung cancer either alone or in combination with Ras inhibitors, and these studies support the potential expansion of future clinical studies in our pipeline." The featured Genprex-supported poster presented at AACR 2025: Title: Overcoming sotorasib acquired resistance in KRASG12C mutant NSCLC by TUSC2 gene therapySession Category: Experimental and Molecular TherapeuticsSession Title: Drug Resistance in Molecular Targeted Therapies 3Session Date and Time: Tuesday, April 29 from 2-5 p.m. CTLocation: Poster Section 17Poster Board Number: 12Abstract Presentation Number: 5517 In the poster, entitled, "Overcoming sotorasib acquired resistance in KRASG12C mutant NSCLC by TUSC2 gene therapy," researchers demonstrated that TUSC2 gene therapy (REQORSA) effectively overcomes sotorasib (LUMAKRAS®) acquired resistance (AR) in KRASG12C mutant NSCLC mouse xenografts. The data indicate that TUSC2 transfection significantly reduced colony formation and markedly increased apoptosis in two AR cell lines. Re-expression of TUSC2 in AR PDXOs significantly decreased the viability of organoids compared with the empty vector. The H23AR tumors exhibited significantly lower sensitivity to sotorasib than their parental counterparts. However, treatment with REQORSA was highly effective in controlling tumor growth compared to treatment with sotorasib alone or the control groups. REQORSA alone also exhibited a strong antitumor effect on TC314AR PDXs. Sotorasib alone showed no significant antitumor activity in these models. However, a synergistic antitumor effect was observed when TC314AR PDX tumors were treated with the combination of REQORSA and sotorasib. In conclusion, researchers demonstrated that REQORSA, alone or in combination with sotorasib, induced apoptosis, inhibited colony formation, and showed significant antitumor efficacy in KRASG12C mutant sotorasib-acquired resistant xenograft and PDX tumors. This AACR poster has been made available on Genprex's website at About Reqorsa® Gene TherapyREQORSA (quaratusugene ozeplasmid) consists of a plasmid containing the TUSC2 gene encapsulated in non-viral lipid-based nanoparticles in a lipoplex form (the Company's Oncoprex® Delivery System), which has a positive charge. REQORSA is injected intravenously and specifically targets cancer cells. REQORSA is designed to deliver the functioning TUSC2 gene to negatively charged cancer cells while minimizing uptake by normal tissue. Laboratory studies conducted at MD Anderson show that the uptake of TUSC2 in tumor cells in vitro after REQORSA treatment was 10 to 33 times the uptake in normal cells. About Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex's oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. The Company's lead product candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), is being evaluated in two clinical trials as a treatment for NSCLC and SCLC. Each of Genprex's lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and Genprex's SCLC program has received an FDA Orphan Drug Designation. Genprex's diabetes gene therapy approach is comprised of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body's immune system. In a similar approach for Type 2 diabetes, where autoimmunity is not at play, GPX-002 is believed to rejuvenate and replenish exhausted beta cells. Interested investors and shareholders are encouraged to sign up for press releases and industry updates by visiting the Company Website, registering for Email Alerts and by following Genprex on Twitter, Facebook and LinkedIn. Cautionary Language Concerning Forward-Looking StatementsStatements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex's reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under "Item 1A – Risk Factors" in Genprex's Annual Report on Form 10-K for the year ended December 31, 2024. Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: REQORSA's potential as a therapeutic treatment for Ras inhibitor resistant lung cancer; Genprex's ability to advance the clinical development, manufacturing and commercialization of its product candidates in accordance with projected timelines and specifications; the timing and success of Genprex's clinical trials and regulatory approvals, the effect of Genprex's product candidates, alone and in combination with other therapies, on cancer and diabetes; the effects of any strategic research and development prioritization initiatives, and any other strategic alternatives or other efforts that Genprex takes or may take in the future that are aimed at optimizing and re-focusing Genprex's diabetes, oncology and/or other clinical development programs including prioritization of resources, and the extent to which Genprex is able to implement such efforts and initiatives successfully to achieve the desired and intended results thereof; Genprex's future growth and financial status, including Genprex's ability to maintain compliance with the continued listing requirements of The Nasdaq Capital Market and to continue as a going concern and to obtain capital to meet its long-term liquidity needs on acceptable terms, or at all; Genprex's commercial and strategic partnerships, including those with its third party vendors, suppliers and manufacturers and their ability to successfully perform and scale up the manufacture of its product candidates; and Genprex's intellectual property and licenses. These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law. Genprex, Inc.(877) 774-GNPX (4679) GNPX Investor Relationsinvestors@ GNPX Media ContactKalyn Dabbsmedia@ View original content to download multimedia: SOURCE Genprex, Inc. Sign in to access your portfolio
Associated Press
30-04-2025
- Business
- Associated Press
Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Ras Inhibitor Resistant Lung Cancer at the 2025 AACR Annual Meeting
Both REQORSA Alone and in Combination with LUMAKRAS® Demonstrated Robust Anti-Tumor Effects in Ras Inhibitor Resistant Non-Small Cell Lung Cancer AUSTIN, Texas, April 30, 2025 /PRNewswire/ -- Genprex, Inc. ('Genprex' or the 'Company') (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators presented positive preclinical data for Reqorsa® Gene Therapy (quaratusugene ozeplasmid), for the treatment of KRASG12C mutant non-small cell lung cancer (NSCLC). This data were presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting being held April 25-30, 2025 in Chicago, Illinois. 'We are pleased to have this positive preclinical data presented before an audience of the world's leading cancer researchers, which provides further support for the therapeutic potential of REQORSA both alone and in combination with targeted therapies in NSCLC,' said Ryan Confer, President and Chief Executive Officer at Genprex. 'We believe REQORSA could be a potential therapeutic treatment for Ras inhibitor resistant lung cancer either alone or in combination with Ras inhibitors, and these studies support the potential expansion of future clinical studies in our pipeline.' The featured Genprex-supported poster presented at AACR 2025: Title: Overcoming sotorasib acquired resistance in KRASG12C mutant NSCLC by TUSC2 gene therapy Session Category: Experimental and Molecular Therapeutics Session Title: Drug Resistance in Molecular Targeted Therapies 3 Session Date and Time: Tuesday, April 29 from 2-5 p.m. CT Location: Poster Section 17 Poster Board Number: 12 Abstract Presentation Number: 5517 In the poster, entitled, 'Overcoming sotorasib acquired resistance in KRASG12C mutant NSCLC by TUSC2 gene therapy,' researchers demonstrated that TUSC2 gene therapy (REQORSA) effectively overcomes sotorasib (LUMAKRAS®) acquired resistance (AR) in KRASG12C mutant NSCLC mouse xenografts. The data indicate that TUSC2 transfection significantly reduced colony formation and markedly increased apoptosis in two AR cell lines. Re-expression of TUSC2 in AR PDXOs significantly decreased the viability of organoids compared with the empty vector. The H23AR tumors exhibited significantly lower sensitivity to sotorasib than their parental counterparts. However, treatment with REQORSA was highly effective in controlling tumor growth compared to treatment with sotorasib alone or the control groups. REQORSA alone also exhibited a strong antitumor effect on TC314AR PDXs. Sotorasib alone showed no significant antitumor activity in these models. However, a synergistic antitumor effect was observed when TC314AR PDX tumors were treated with the combination of REQORSA and sotorasib. In conclusion, researchers demonstrated that REQORSA, alone or in combination with sotorasib, induced apoptosis, inhibited colony formation, and showed significant antitumor efficacy in KRASG12C mutant sotorasib-acquired resistant xenograft and PDX tumors. This AACR poster has been made available on Genprex's website at About Reqorsa® Gene Therapy REQORSA (quaratusugene ozeplasmid) consists of a plasmid containing the TUSC2 gene encapsulated in non-viral lipid-based nanoparticles in a lipoplex form (the Company's Oncoprex® Delivery System), which has a positive charge. REQORSA is injected intravenously and specifically targets cancer cells. REQORSA is designed to deliver the functioning TUSC2 gene to negatively charged cancer cells while minimizing uptake by normal tissue. Laboratory studies conducted at MD Anderson show that the uptake of TUSC2 in tumor cells in vitro after REQORSA treatment was 10 to 33 times the uptake in normal cells. About Genprex, Inc. Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex's oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. The Company's lead product candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), is being evaluated in two clinical trials as a treatment for NSCLC and SCLC. Each of Genprex's lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and Genprex's SCLC program has received an FDA Orphan Drug Designation. Genprex's diabetes gene therapy approach is comprised of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body's immune system. In a similar approach for Type 2 diabetes, where autoimmunity is not at play, GPX-002 is believed to rejuvenate and replenish exhausted beta cells. Interested investors and shareholders are encouraged to sign up for press releases and industry updates by visiting the Company Website, registering for Email Alerts and by following Genprex on Twitter, Facebook and LinkedIn. Cautionary Language Concerning Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex's reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under 'Item 1A – Risk Factors' in Genprex's Annual Report on Form 10-K for the year ended December 31, 2024. Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: REQORSA's potential as a therapeutic treatment for Ras inhibitor resistant lung cancer; Genprex's ability to advance the clinical development, manufacturing and commercialization of its product candidates in accordance with projected timelines and specifications; the timing and success of Genprex's clinical trials and regulatory approvals, the effect of Genprex's product candidates, alone and in combination with other therapies, on cancer and diabetes; the effects of any strategic research and development prioritization initiatives, and any other strategic alternatives or other efforts that Genprex takes or may take in the future that are aimed at optimizing and re-focusing Genprex's diabetes, oncology and/or other clinical development programs including prioritization of resources, and the extent to which Genprex is able to implement such efforts and initiatives successfully to achieve the desired and intended results thereof; Genprex's future growth and financial status, including Genprex's ability to maintain compliance with the continued listing requirements of The Nasdaq Capital Market and to continue as a going concern and to obtain capital to meet its long-term liquidity needs on acceptable terms, or at all; Genprex's commercial and strategic partnerships, including those with its third party vendors, suppliers and manufacturers and their ability to successfully perform and scale up the manufacture of its product candidates; and Genprex's intellectual property and licenses. These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law. Genprex, Inc. (877) 774-GNPX (4679) GNPX Investor Relations [email protected] GNPX Media Contact Kalyn Dabbs [email protected] View original content to download multimedia: SOURCE Genprex, Inc.
